OSE Immunotherapeutics SA
EPA:OSE.PA
6.05 (EUR) • At close June 5, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) EUR.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 69.877 | 2.227 | 18.302 | 26.306 | 10.418 | 25.952 | 24.456 | 6.682 | 0.383 | 0.004 | 0 | 0 | 0 |
| Cost of Revenue
| 69.877 | 0 | 0 | 0 | -0.001 | 0.008 | 0.004 | 0 | 0.016 | 0.013 | 0 | 0 | 0 |
| Gross Profit
| 0 | 2.227 | 18.302 | 26.306 | 10.419 | 25.944 | 24.452 | 6.682 | 0.383 | -0.009 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | -2.25 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 30.445 | 17.158 | 29.903 | 33.962 | 27.842 | 25.091 | 15.057 | 14.641 | 8.031 | 2.245 | 2.133 | 0.154 | 1.309 |
| General & Administrative Expenses
| 6.26 | 5.962 | 6.594 | 8.503 | 4.701 | 3.855 | 3.421 | 3.146 | 2.773 | 1.318 | 0.663 | 0.09 | 0.136 |
| Selling & Marketing Expenses
| 2.724 | 2.034 | 3.13 | 3.773 | 0.064 | 1.585 | 0.977 | 1.505 | 0.679 | 0 | 0.135 | 0 | 0 |
| SG&A
| 0.395 | 0.068 | 8.801 | 11.577 | 6.984 | 5.723 | 4.398 | 4.651 | 3.452 | 3.175 | 0.798 | 0.09 | 0.136 |
| Other Expenses
| -5.081 | 0 | -0.078 | -0.134 | -5.664 | -3.546 | -4.479 | -3.91 | -28.599 | -0.69 | 0 | 0 | 0 |
| Operating Expenses
| 33.446 | 25.213 | 38.782 | 45.673 | 29.407 | 27.416 | 19.598 | 19.388 | -17.114 | 5.424 | 2.837 | 0.25 | 1.445 |
| Operating Income
| 30.174 | -22.986 | -18.476 | -16.625 | -18.989 | -1.472 | 4.847 | -12.626 | 17.499 | -5.42 | -2.815 | -0.25 | -1.445 |
| Operating Income Ratio
| 0.432 | -10.322 | -1.01 | -0.632 | -1.823 | -0.057 | 0.198 | -1.89 | 45.689 | -1,355 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -3.903 | -0.235 | 0.454 | -0.588 | -0.257 | 0.008 | -0.14 | -0.115 | 0.093 | -0.153 | -0.018 | 0 | 0.009 |
| Income Before Tax
| 39.832 | -23.222 | -23.454 | -21.558 | -24.367 | -4.523 | 4.707 | -12.741 | 17.592 | -5.573 | -2.833 | -0.25 | -1.436 |
| Income Before Tax Ratio
| 0.57 | -10.427 | -1.281 | -0.82 | -2.339 | -0.174 | 0.192 | -1.907 | 45.932 | -1,393.25 | 0 | 0 | 0 |
| Income Tax Expense
| 2.387 | -0.219 | -5.694 | -4.708 | -2.692 | 3.188 | -0.783 | -2.238 | -3.074 | 0.011 | 0.002 | 0.25 | 1.745 |
| Net Income
| 37.445 | -23.003 | -17.76 | -16.85 | -16.555 | -4.652 | 5.49 | -10.503 | 20.666 | -5.584 | -2.835 | -0.25 | -1.436 |
| Net Income Ratio
| 0.536 | -10.329 | -0.97 | -0.641 | -1.589 | -0.179 | 0.224 | -1.572 | 53.958 | -1,396 | 0 | 0 | 0 |
| EPS
| 1.72 | -1.18 | -0.96 | -0.93 | -1.06 | -0.31 | 0.35 | -0.73 | 1.65 | -0.59 | -0.36 | -0.033 | -0.18 |
| EPS Diluted
| 1.48 | -1.18 | -0.96 | -0.93 | -1.06 | -0.31 | 0.35 | -0.73 | 1.52 | -0.59 | -0.36 | -0.033 | -0.18 |
| EBITDA
| 46.314 | -17.501 | -13.113 | -13.72 | -18.243 | -0.801 | 5.009 | -12.541 | 15.311 | -5.431 | -0.018 | -0.25 | -1.436 |
| EBITDA Ratio
| 0.663 | -7.859 | -0.716 | -0.522 | -1.751 | -0.031 | 0.205 | -1.877 | 39.977 | -1,357.75 | 0 | 0 | 0 |